Knut Jørgen Labori
A5032849503- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Renal cell carcinoma treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Treatments and Studies
- Neonatal Health and Biochemistry
- Epigenetics and DNA Methylation
- Drug Transport and Resistance Mechanisms
- Cancer Research and Treatments
- Liver Disease and Transplantation
- Pediatric Hepatobiliary Diseases and Treatments
- Organ Transplantation Techniques and Outcomes
- Lung Cancer Research Studies
- Colorectal and Anal Carcinomas
- Esophageal and GI Pathology
- Aortic aneurysm repair treatments
- MRI in cancer diagnosis
Oslo University Hospital
2016-2025
University of Oslo
2004-2025
Institutt for Eksperimentell Medisinsk Forskning
2000-2009
LBA4005 Background: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has shown improved survival in metastatic pancreatic cancer, promising results as downstaging chemotherapy locally advanced cancer. The efficacy of neoadjuvant FOLFIRINOX patients with resectable cancer is unknown. Methods: This a randomized phase II trial included from 12 Nordic centers the period 2017-2021. Patients head were randomly assigned to receive either four cycles followed by surgery eight...
Multimodality treatment (MMT) improves survival for patients with pancreatic ductal adenocarcinoma (PDAC). The surgery-first (SF) strategy is the most universally accepted approach.Population-based retrospective cohort study of all cases resectable PDAC from 2006 to 2012. Patients were planned adjuvant chemotherapy (AC) Nordic 5-fluorouracil/leucovorin regimen. Reasons and rates failure complete AC, postoperative major complications (PMC), overall (OS) analysed.Of 203 patients, 85 (41.9%)...
<h3>Importance</h3> The benefit of adjuvant chemotherapy after resection pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. <h3>Objective</h3> To assess the association overall survival (OS) in patients FOLFIRINOX treatment. <h3>Design, Setting, Participants</h3> This international, multicenter, retrospective cohort study was conducted from January 1, 2012, to December 31, 2018. An existing...
Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains foundation for potentially curative treatment, survival benefit achieved with adjuvant oncological treatment. Thus, completion multimodality treatment (surgical and (neo)adjuvant chemotherapy) to all patients early micrometastatic disease ideal goal. NorPACT–1 aims test hypothesis that overall mortality at one year after allocation can be reduced neoadjuvant chemotherapy in surgically...
Abstract Background Western multicenter studies on distal pancreatectomy with celiac axis resection (DP-CAR), also known as the Appleby procedure, for locally advanced pancreatic cancer are lacking. We aimed to study overall survival, morbidity, mortality and impact of preoperative hepatic artery embolization (PHAE). Methods Retrospective cohort within European-African Hepato-Pancreato-Biliary-Association, DP-CAR between 1-1-2000 6-1-2016. Primary endpoint was survival. Secondary endpoints...
Abstract Background Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients resectable pancreatic cancer. The main concern regarding chemotherapy that only half actually receive treatment. Neoadjuvant chemotherapy, on other hand, guarantees early systemic treatment may increase use thereby improve overall survival. Furthermore, it prevent futile surgery in rapidly progressive disease....
Importance Preoperative chemo(radio)therapy is increasingly used in patients with localized pancreatic adenocarcinoma, leading to pathological complete response (pCR) a small subset of patients. However, multicenter studies in-depth data about pCR are lacking. Objective To investigate the incidence, outcome, and risk factors after preoperative chemo(radio)therapy. Design, Setting, Participants This observational, international, cohort study assessed all consecutive pathology-proven...
Importance The effect of adjuvant chemotherapy following resection pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) on overall survival (OS) is unclear because current studies do not account for the number cycles regimen. Objective To investigate association with OS, taking into Design, Setting, Participants This retrospective cohort study included...
Meticulous imaging of colorectal liver metastases (CRLM) is mandatory to optimize outcome after resection. However, the detection CRLM still challenging.To evaluate prospectively if magnetic resonance (MRI) with diffusion-weighted and Gd-EOB-DTPA-enhanced sequences had a better diagnostic performance for compared computed tomography (CT) fluorine-18 fluorodeoxyglucose positron emission (PET/CT).Forty-six patients scheduled resection suspected were evaluated from September 2011 January 2013....
Pancreatic ductal adenocarcinoma (PDAC) is highly infiltrated by CD4+T cells that express RORγt and IL-17 (TH17). Compelling evidence from the tumor microenvironment suggest regulatory T (Treg) contribute to TH17 mediated inflammation. Concurrently, PDAC patients have elevated levels of pro-inflammatory cytokines may lead associated functional plasticity in Treg. In this study, we investigated phenotype properties Treg with PDAC. We report frequency FOXP3+Treg, which exclusively occurred...
Abstract Background Pancreatoduodenectomy with superior mesenteric–portal vein resection has become a common procedure in pancreatic surgery. The aim of this study was to compare standard pancreatoduodenectomy plus venous at high-volume centre, and examine trends management outcome over decade for the latter procedure. Methods This retrospective observational included all patients undergoing or without Oslo University Hospital between January 2006 December 2015. Trends were evaluated by...
We evaluated the prognostic impact of circulating tumor cells (CTCs) for patients with presumed resectable pancreatic and periampullary cancers.Initial treatment decisions this group are currently taken without a reliable marker. The CellSearch system allows standardized CTC-testing has shown excellent specificity value in other applications.Preoperative blood samples from 242 between September 2009 December 2014 were analyzed. One hundred seventy-nine underwent resection, whom 30 stage-I...
In patients with presumed pancreatic ductal adenocarcinoma (PDAC), biomarkers that may open for personalised, risk-adapted treatment are lacking. The study analysed the impact of CTCs-presence on patterns recurrence and survival in 98 resected PDAC 5–10 years follow-up. Preoperative samples were by CellSearch® system EpCAM+/DAPI+/CK+/CD45-CTCs. CTCs detected 7 patients. predicted a significantly shorter median disease-free (DFS) 3.3 vs. 9.2 months cancer specific (CSS)of 6.3 18.5 months....
Systemic chemotherapy is the initial treatment strategy for borderline resectable and locally advanced pancreatic cancer to facilitate curative resection. The aim of this study was investigate resection rates overall survival in patients with cancer.
Abstract Despite advances in diagnostics, less than 5% of patients with periampullary tumors experience an overall survival five years or more. Periampullary are neoplasms that arise the vicinity ampulla Vater, enlargement liver and pancreas ducts where they join enter small intestine. In this study, we analyzed copy number aberrations using Affymetrix SNP 6.0 arrays 60 adenocarcinomas from Oslo University Hospital to identify genome-wide aberrations, putative driver genes, deregulated...
To assess the association between neoadjuvant therapy and overall survival (OS) in patients with left-sided resectable pancreatic cancer (RPC) compared to upfront surgery. Left-sided is associated worse OS right-sided cancer. Although currently seen as not effective RPC, current randomized trials included mostly RPC. International multicenter retrospective study including consecutive after resection for pathology-proven either or surgery 76 centers from 18 countries on 4 continents...
<title>Abstract</title> <bold>Background</bold> Based on current guidelines, surgical treatment of hepatic oligometastases in patients with pancreatic ductal adenocarcinoma (PDAC) is not primarily recommended. Systematic chemotherapy the therapy choice for these patients. The relevance subsequent resection after remains unclear. This multicentre, randomized, controlled phase III trial planned to evaluate whether primary tumor and liver metastases can improve overall survival PDAC a...